CAI|Caris Life Sciences Inc|Price:16.580|Chg%:-1.75

More Details of Caris Life Sciences Inc Company

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Caris Life Sciences Inc Info



Ticker SymbolCAI

Company nameCaris Life Sciences Inc

IPO dateJun 18, 2025

CEOHalbert (David Dean)

Number of employees- -

Security typeOrdinary Share

Fiscal year-endJun 18

Address750 W. John Carpenter Freeway

CityIRVING

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code75039

Phone18667718946

Websitehttps://www.carislifesciences.com/

Ticker SymbolCAI

IPO dateJun 18, 2025

CEOHalbert (David Dean)

Company Executives of Caris Life Sciences Inc



Name

Name/Position

Position

Shareholding

Change

Dr. George H. Poste, Ph.D.

Vice Chairman of the Board

511.70K

-2.84%

Mr. Luke Power

Chief Financial Officer, Senior Vice President, Chief Accounting Officer

163.54K

+39.12%

Mr. David (Dave) Fredrickson

Independent Director

2.49K

-547.23%

Mr. Peter M. Castleman

Lead Independent Director

--

Mr. Joseph E. Gilliam

Independent Director

--

Mr. Jon S. Halbert

Director

--

Ms. Laura I. Johansen

Independent Director

--

Dr. Lloyd B. Minor, M.D.

Independent Director

--

Mr. Vijay Mohan

Independent Director

--

Mr. Danny Phillips

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. George H. Poste, Ph.D.

Vice Chairman of the Board

511.70K

-2.84%

Mr. Luke Power

Chief Financial Officer, Senior Vice President, Chief Accounting Officer

163.54K

+39.12%

Mr. David (Dave) Fredrickson

Independent Director

2.49K

-547.23%

Mr. Peter M. Castleman

Lead Independent Director

--

Mr. Joseph E. Gilliam

Independent Director

--

Mr. Jon S. Halbert

Director

--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6

FY2025Q3

FY2025Q2

Relevant data have not been disclosed by the company yet.

By RegionUSD

Name

Revenue

Proportion

United States

213.55M

98.49%

International

3.28M

1.51%

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Fri, Mar 20

Shareholders

Shareholder Types

Shareholders

Proportion

Halbert (David D)

43.56%

J.H. Whitney Capital Partners, LLC

7.17%

Sixth Street Partners, LLC

6.86%

Fidelity Management & Research Company LLC

4.48%

Castleman Peter M

3.67%

Other

34.26%

Shareholders

Proportion

Halbert (David D)

43.56%

J.H. Whitney Capital Partners, LLC

7.17%

Sixth Street Partners, LLC

6.86%

Fidelity Management & Research Company LLC

4.48%

Castleman Peter M

3.67%

Other

34.26%

Shareholder Types

Shareholders

Proportion

Individual Investor

48.61%

Investment Advisor

30.05%

Hedge Fund

14.08%

Private Equity

8.70%

Investment Advisor/Hedge Fund

4.87%

Research Firm

0.92%

Pension Fund

0.58%

Sovereign Wealth Fund

0.04%

Bank and Trust

0.02%

Institutional Shareholding



Updated: Wed, Jan 21

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q4

228

134.49M

38.87%

--

2025Q4

261

137.01M

48.56%

+26.69M

2025Q3

172

130.04M

46.09%

+127.36M

2025Q2

45

192.42M

69.23%

+189.87M

2025Q1

3

2.55M

0.92%

+2.55M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Halbert (David D)

122.76M

43.51%

-141.96K

-0.12%

Aug 11, 2025

J.H. Whitney Capital Partners, LLC

20.26M

7.18%

+20.26M

--

Jun 30, 2025

Sixth Street Partners, LLC

24.39M

8.64%

--

Sep 30, 2025

Fidelity Management & Research Company LLC

9.58M

3.39%

+963.04K

+11.18%

Sep 30, 2025

Castleman Peter M

10.37M

3.68%

+10.34M

+32049.87%

Jun 18, 2025

Coatue Management, L.L.C.

10.14M

3.59%

--

Sep 30, 2025

T. Rowe Price Investment Management, Inc.

8.03M

2.84%

+721.77K

+9.88%

Sep 30, 2025

Braidwell LP

7.32M

2.59%

--

Sep 30, 2025

PointState Capital LP

3.88M

1.38%

+1.39M

+55.45%

Sep 30, 2025

T. Rowe Price Associates, Inc.

6.92M

2.45%

+154.50K

+2.29%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

ARK Genomic Revolution ETF

0.67%

Texas Capital Texas Small Cap Equity Index ETF

0.52%

Renaissance IPO ETF

0.43%

RiverNorth Patriot ETF

0.3%

Franklin Genomic Advancements ETF

0.29%

Invesco Russell 1000 Equal Weight ETF

0.08%

Inspire 500 ETF

0.07%

T Rowe Price Small-Mid Cap ETF

0.05%

Texas Capital Texas Equity Index ETF

0.04%

Fidelity Nasdaq Composite Index ETF

0.02%

ARK Genomic Revolution ETF

Proportion0.67%

Texas Capital Texas Small Cap Equity Index ETF

Proportion0.52%

Renaissance IPO ETF

Proportion0.43%

RiverNorth Patriot ETF

Proportion0.3%

Franklin Genomic Advancements ETF

Proportion0.29%

Invesco Russell 1000 Equal Weight ETF

Proportion0.08%

Inspire 500 ETF

Proportion0.07%

T Rowe Price Small-Mid Cap ETF

Proportion0.05%

Texas Capital Texas Equity Index ETF

Proportion0.04%

Fidelity Nasdaq Composite Index ETF

Proportion0.02%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data